V12 SENTINEL ENGINE · AI MARKET ANALYSIS
Mid
N
NVAXAI Stock Diagnostic Report

Novavax expects $235M-$275M in 2026 adjusted total revenue while targeting $150M-$200M in 2028 non-GAAP R&D and SG&A

Novavax has presented its revenue and expense targets for 2026 and 2028, along with a capital-efficient operating model and a partnership-focused strategy.

View Source Article ↗
AI CATALYST SCORE75 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+
ANALYSIS HISTORY

NVAX Analysis History (Last 30 Days)

Diagnosed AtTickerAI ScoreTier
2026-08-28 13:31:33NVAX75MidView Report →
2026-08-06 22:29:25NVAX75MidView Report →
2026-08-06 12:46:59NVAX85MidView Report →
View Full History for NVAX (Blueprint) →